Evidence map›Paper›PMID 35607279›Full record

SynthesisLupus2022

Health-related quality of life, fatigue and health utilities in lupus nephritis: A systematic literature review.

Saifuddin Kharawala, Gavneet Kaur, Hemlata Shukla, David Alexander Scott, Neil Hawkins, Wen-Hung Chen, Kerry Gairy

Open access · hybridAbstract readSystematic Review
In one paragraph

Synthesis in Lupus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Lupus nephritis.Nature reviews. Disease primers · 2025
    Review
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Saifuddin Kharawala475573Bridge Medical Consulting Ltd., London, UK.
Gavneet Kaur475573Bridge Medical Consulting Ltd., London, UK.
Hemlata Shukla475573Bridge Medical Consulting Ltd., London, UK.
David Alexander Scott475573Bridge Medical Consulting Ltd., London, UK.
Neil Hawkins475573Bridge Medical Consulting Ltd., London, UK.
Wen-Hung ChenPatient Centered Outcomes, 1929GlaxoSmithKline, Collegeville, PA, USA.
Kerry GairyValue Evidence & Outcomes, 1929GlaxoSmithKline, Brentford, Middlesex, UK.ORCID https://orcid.org/0000-0001-8591-1396
GlaxoSmithKline (United Kingdom) · GBGlaxoSmithKline (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSystemic lupus erythematosus (SLE) is a chronic, autoimmune disease characterized by abnormal B-cell activation and the presence of autoantibodies, which can result in organ damage. Lupus nephritis (LN) is the most common severe organ manifestation of SLE and may result in impaired kidney function. However, there is limited research on the health-related quality of life (HRQoL) burden amongst patients with LN. The objective of this systematic literature review was to assess the HRQoL, fatigue and health utilities associated with LN.

methodsA structured literature search (GSK Study 212980) of the MEDLINE and Embase databases was conducted in July 2019 and updated September 2021. Relevant international congress abstracts from 2016 to 2021 were searched, and gray literature searches and keyword-based searches in PubMed, Google, and Google Scholar were also conducted. Results were screened according to predefined criteria and data on the outcomes of interest were extracted. A quantitative analysis was conducted to supplement the narrative review, to provide 36-item Short Form survey (SF-36) estimates, and to determine variation by prognostic factors.

resultsOf 1155 articles identified, 26 studies for a total of 3440 patients were included. Patients with LN showed poorer HRQoL and more fatigue than healthy controls/the general population, although these were similar between patients with SLE with and without LN. HRQoL was worse in patients with LN Class III/IV or with active disease. Fatigue was generally reported as the most burdensome symptom and was associated with lower HRQoL and increased treatment dissatisfaction. During induction treatment, HRQoL and fatigue were improved with mycophenolate mofetil versus cyclophosphamide. HRQoL improved over time with treatment amongst patients with active LN. Very limited data were identified assigning utilities to health states for cost-effectiveness analysis. Nine studies were considered for quantitative analysis of baseline SF-36 scores. The analysis suggested that LN has a significant impact across all SF-36 domains, with the lowest scores in the general health perceptions and role-physical domains and physical component summary.

conclusionsThere is a large HRQoL burden in patients with LN, in particular regarding symptoms of fatigue. Future research should focus on investigating fatigue severity and health utilities in LN.

Indexed as

Lupus Erythematosus, SystemicLupus NephritisFatigueHumansQuality of LifeSeverity of Illness Indexfatiguehealth-related quality of lifehealth utilitiesLupus erythematosuslupus nephritissystemic

Identifiers

PMID35607279
PMCPMC9277333
OpenAlexW4281382531

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.